Evaxion Biotech A/S (NASDAQ:EVAX) traded with a subtraction of -$0.04 to close at $1.73 on Friday, a downside of -2.08 percent. An average of 520,316 shares of common stock have been traded in the last five days. There was a fall of -$0.0300 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 154,824 shares traded, while the 50-day average volume stands at 72,946.
EVAX stock has decreased by -17.83% in the last month. The company shares reached their 1-month lowest point of $1.6800 on 12/12/22. With the stock rallying to its 52-week high on 01/06/22, shares of the company touched a low of $1.51 and a high of $4.67 in 52 weeks. It has reached a new high 3 times so far this year and lost -60.03% or -$2.6500 in price. In spite of this, the price is down -62.97% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
The quick ratio of Evaxion Biotech A/S for the three months ended September 29 was 6.50, and the current ratio was 6.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.46 and a total debt to equity ratio of 0.48 for the quarter ending September 29. Its gross profit as reported stood at $0.92 million compared to revenue of $25.83 million.
For the three-month period that ended September 29, Evaxion Biotech A/S had $0.84 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$24.53 million in the quarter, while revenues were grew 38.77%. The analyst consensus anticipated Evaxion Biotech A/S’s latest quarter earnings to come in at -$0.27 per share, but it turned out to be -$0.24, a 11.10% surprise. At the end of the quarter ending September 29, Evaxion Biotech A/S’s stock balance sheet showed total debt was $9.72 million.
From a technical analysis perspective, let’s take a brief look at Evaxion Biotech A/S (EVAX) price momentum. RSI 9-day as of the close on 29 December was 38.23%, suggesting the stock is Neutral, with historical volatility in this time frame at 42.61%.
As of today, EVAX’s price is $1.7573 -1.67% or -$0.0300 from its 5-day moving average. EVAX is currently trading -20.63% lower than its 20-day SMA and -36.79% lower than its 100-day SMA. However, the stock’s current price level is -41.39% below the SMA50 and -33.71% below the SMA200.
The stochastic %K and %D were 12.59% and 11.93%, respectively, and the average true range (ATR) was 0.2040. With the 14-day stochastic at 15.00% and the average true range at 0.2024, the RSI (14) stands at 37.98%. The stock has reached -0.0318 on the 9-day MACD Oscillator while the 14-day reading was at -0.0810.
The consensus rating for Evaxion Biotech A/S (EVAX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell EVAX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is EVAX’s price target for the next 12 months?
Analysts predict a range of price targets between $11.00 and $18.00, with a median target of $15.00. Taking a look at these predictions, the average price target given by analysts for Evaxion Biotech A/S (EVAX) stock is $14.67.